AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
13:57
EASA and EUROCONTROL prepare authorities for new air traffic controller training rules from 2029
13:48
Dominic Fritz proposes a center-right reformist coalition for the 2028 elections
13:31
Two Romanians arrested in Italy after allegedly stealing more than €2,300 worth of products from supermarkets
13:15
EU and Canada sign two space agreements, while access to Galileo services will be negotiated separately
13:10
Transport operators report problems with TollRo, while CNAIR cannot say how many fines have been issued
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
